Abstract:e23122 Background: Tumor heterogeneity represents a key hallmark of cancer which complicates anti-cancer treatments. Presence of sub-clonal tumor population may be undetected through bulk tumor sequencing, and may emerge as dominant tumor clone in the course of therapy. This limitation may potentially be surmounted with longitudinal genomic analysis of circulating tumor cells (CTC) at single cell level. Methods: Peripheral blood samples from metastatic gastrointestinal (gastric, colorectal, and pancreatic) cancer pts were enriched for CTCs using ClearCell FX system (Clearbridge Biomedics). Enriched samples were fluorescently labelled with DAPI, EpCAM and CD45 antibodies to aid identification and recovery of single CTC/CTC clusters using micropipette. Whole genome sequencing was performed on individual cells/clusters, following MALBAC whole genome amplification (Yikon Genomics). Copy number variation (CNV) profile of CTCs were analyzed to identify chromosomal gains and losses. HeLa cells were used as positive control to verify the assay. Results: A total of 40 cells (23 CTCs and 17 leukocytes) were recovered from 5 metastatic cancer pts. Both EpCAM-expressing(10%) and EpCAM-negative(90%) CTCs were identified. 38 cells were successfully amplified and sequenced with average mapping rate of 95%. Copy number variation profile analysis revealed an elevated level of copy number alterations among putative CTCs (CD45-/DAPI+). Two distinct CNV profiles were observed in one of the colorectal patients, indicative of genomic heterogeneity or sub-clonal population. Conclusions: Individual CTCs from gastrointestinal cancer pts were successfully recovered and sequenced. Information on heterogeneity of CTCs can be harnessed to study the emergence and underlying mechanisms of drug resistance. CTC liquid biopsy presents an opportunity for longitudinal monitoring of pt mutation profile throughout treatment.

Single Cell Copy Number Variation Analysis of Circulating Tumor Cells in Gastrointestinal Cancer Patients for Study of Intra-Patient Genomic Heterogeneity.